186519-85-7

Upstream product

• 54060-30-9 3-acetylenephenylamine 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 3680-71-5 7-deazahypoxanthine 

Downstream Products

• 865364-80-3 4-(3-ethynyl-phenylamino)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one 

Relevant academic research and scientific papers

Heterocyclic ring-fused pyrimidine derivatives

The present invention relates to heterocyclic ring-fused pyrimidine derivatives of formula (I) or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof, wherein Z and Y are as defined in the specification. Compounds of formula (I) are useful in the treatment of hyperproliferative diseases, such as cancers and acnes, in mammals:

Rational design of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones as a novel class of inhibitors of epidermal growth factor receptor (EGF-R) and Her2(p185(erbB)) tyrosine kinases.

A novel class of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones has been discovered as potent and selective inhibitors of the EGF-R tyrosine kinase family. These compounds selectively inhibit EGF-R kinase activity at low nanomolar concentration and tyrosine autophosphorylation in cells expressing EGF-R or Her2 (p185(erbB)). Structure-activity relationships (SARs) for this class of compounds are presented.